Advanced Materials · IP Licensing Platform · IIT Delhi Validated
Four patent families spanning targeted drug delivery, real-time oxygen sensing, industrial carbon capture, and satellite materials. Characterization complete. Cancer cell efficacy data in progress — expected October 2026.
Patent Portfolio
Same foundational MOF chemistry. Four distinct billion-dollar markets. Each platform independently licensable with its own data package and buyer profile.
Azobenzene-based Zr-MOF triggers drug release exclusively in hypoxic tumor microenvironments via azo-bond reductive cleavage. Drug loads directly within the MOF — no liposome required. Cisplatin-validated with 45.86% avg drug loading and 84.82% avg encapsulation efficiency across three independent samples. PXRD confirms structural collapse onset at 1 hour under hypoxia; full stability under normoxia.
Phosphorescent Cu(I)-TPYM complexes and pyridylimine-functionalized MOFs detect intratumoral oxygen tension in real time via phosphorescence quenching — up to 85% within 20 minutes. Closed-loop theranostic: single construct maps O₂ AND triggers drug release. Autonomous Narcan delivery mechanism: opioid-induced O₂ drop detected, naloxone released without injection or bystander.
Six MOF formula families — imidazolate ZIFs, amino-functionalized frameworks, MOF-74 DOBDC series, mixed-metal MOFs, transition metal organometallics, and NHC complexes — targeting CO₂ capture from power generation, cement, steel, and chemical manufacturing. Also covers catalytic CO₂ conversion to methanol, formic acid, and bioplastics.
Five formula families engineered for extreme space environments: lanthanide-based (Gd/Hf) for neutron and gamma-ray shielding, Zr UiO series for 500°C thermal stability, Zn-MOFs for lightweight gas storage, Fe/Cr porphyrin MOFs for ISRU catalysis, and ZIFs for CO₂ scrubbing in manned missions. Covers LEO, GEO, lunar, and Mars profiles.
Validated Results
Full characterization suite complete on CWY001 AZO-ZR MOF platform. Three independent reproducible samples. Cancer cell efficacy studies currently in progress.
Hypoxia: >5.4 mg released by 72h. Normoxia: <2.4 mg. Mechanistically driven by azo-bond reductive cleavage — confirmed by PXRD structural collapse at 1hr under hypoxia.
Additional analyses confirmed: SEM (clustered nanoscale morphology), BJH pore diameter 1.48nm, total pore volume 0.32 cm³/g, zeta potential −14.8 mV. Full data package available under NDA.
| Sample | DL% | EE% |
|---|---|---|
| Sample 1 | 43.87% | 78.15% |
| Sample 2 | 46.99% | 88.66% |
| Sample 3 | 46.71% | 87.65% |
Physical and chemical characterization of the AZO-ZR MOF platform is complete. The next phase — currently underway at IIT Delhi — will demonstrate what matters most to pharma partners: cancer cell treatment effectiveness and reduced toxicity to healthy cells.
Cell studies are running on A549 (lung adenocarcinoma) and MCF-7 (breast cancer) cell lines. Outputs will include IC50 values under hypoxic vs. normoxic conditions, cancer cell vs. healthy cell selectivity ratios, and gene expression profiling. This data will directly support the CWY001 licensing conversation with pharma BD teams.
Development Status
All four families are available for licensing now. CWY001 and CWY002 have the deepest data packages. Cancer cell studies will close the remaining gap for pharma partners.
Business Model
Pure IP licensing. We develop and validate; partners manufacture, distribute, and commercialize. Every structure is negotiable across geography and field of use.
Single licensee per field of use. Upfront fee + milestone payments + royalty on net sales. Full technical support from inventors included. Target first deal: $2–5M upfront on CWY001/002, 12–18 months post-data.
Up to two licensees sharing rights across defined indication areas or geographies. Preferred for multi-indication platforms where parallel development accelerates time-to-market.
Field-of-use restricted access for multiple partners. Ideal for platform technologies deployed across distinct verticals — oncology + industrial CCS, for example.
Time-limited exclusivity window for diligence, feasibility studies, and IND-enabling work before committing to full license terms. Entry point for early-stage pharma conversations.
Get in Touch
Full synthesis protocols, characterization data, cisplatin release kinetics, and encapsulation results available under NDA. Cancer cell IC50 and selectivity data released to active licensee conversations upon completion (October 2026).